Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement.

Created on 17 Sep 2026

Authors

Moath Alarabiyat, Sarah Powell-Brett, Saad Rehman, Peter Labib, Ravi Marudanayagam, Bobby Dasari, Syed Soulat Raza, David Bartlett, Keith Roberts, Robert Sutcliffe, Nikolaos Chatizacharias

Published in

ANZ journal of surgery. Sep 16, 2026. Epub Sep 16, 2026.

Abstract

Extensive vascular involvement remains a major challenge in the surgical management of borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC). Temporary mesocaval shunting (tMCS) may facilitate resection in cases of mesenteric venous occlusion or collateralisation and improve exposure of the superior mesenteric artery; however, its use in pancreatic surgery is rarely reported.
We performed a retrospective case series of patients with borderline or locally advanced PDAC who underwent curative-intent resection with intra-operative tMCS between 2017 and 2022. Demographics, perioperative outcomes, post-operative complications and survival were analysed using the Kaplan-Meier method.
Six patients underwent pancreatectomy with tMCS (three pancreaticoduodenectomies, three total pancreatectomies). Median age was 58.5 years. All shunts used cryopreserved cadaveric iliac vein grafts. Median length of stay was 13 days. Two patients (33%) developed Clavien-Dindo grade ≥III complications, including one post-operative death. R0 resection was achieved in two patients (33%). Median overall survival was 24.8 months (33.2 months excluding post-operative mortality), and median disease-free survival was 8 months.
Selective tMCS may enable resection in PDAC with extensive vascular involvement. This complex approach should be reserved for carefully selected patients at high-volume centres with vascular expertise.

PMID:
42749472
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement